

IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

We claim:

1-38. (cancelled)

39. (new) A method of treating Type I diabetes mellitus, which comprises administering a therapeutically-effective amount of melagatran, or a pharmaceutically-acceptable derivative thereof, to a patient in need of such treatment.

40. (new) A method as claimed in Claim 39, wherein the derivative of melagatran is a prodrug of melagatran.

41. (new) A method as claimed in Claim 39, wherein the derivative of melagatran is a prodrug of the formula



wherein R^1 represents linear or branched C_{1-6} alkyl and the OH group replaces one of the amidino hydrogens in Pab.

42. (new) A method as claimed in Claim 41, wherein R^1 represents methyl, ethyl, *n*-propyl, *i*-propyl or *t*-butyl.

43. (new) A method as claimed in Claim 41, wherein R^1 represents ethyl.

44. (new) A method of transplantation of cells, which method comprises the administration of a therapeutically-effective amount of melagatran, or a pharmaceutically-acceptable derivative thereof, to a patient about to be, being, or having been, subjected to such transplantation.

45. (new) A method as claimed in Claim 44, wherein the cells are insulin-producing cells or precursors thereof.

46. (new) A method as claimed in Claim 44, wherein the cells are islets of Langerhans.

47. (new) A method as claimed in Claim 44, wherein the cells are precursors of insulin-producing cells which are stem cells.

48. (new) A method as claimed in any one of Claims 44 to 46, wherein the derivative of melagatran is a prodrug of melagatran.

49. (new) A method as claimed in any one of Claims 44 to 46, wherein the derivative of melagatran is a prodrug of the formula



wherein R^1 represents linear or branched C_{1-6} alkyl and the OH group replaces one of the amidino hydrogens in Pab.

50. (new) A method as claimed in Claim 49, wherein R^1 represents methyl, ethyl, *n*-propyl, *i*-propyl or *t*-butyl.

51. (new) A method as claimed in Claim 49, wherein R^1 represents ethyl.

52. (new) A method of engrafting islets of Langerhans, which method comprises administering a therapeutically-effective amount of melagatran, or a pharmaceutically-acceptable derivative thereof, to a patient about to be, being, or having been, subjected to transplantation of such islets.

53. (new) A method as claimed in Claim 52, wherein the islets engraft in the liver.

54. (new) A method as claimed in Claims 52 or Claim 53, wherein the derivative of melagatran is a prodrug of melagatran.

55. (new) A method as claimed in Claims 52 or Claim 53, wherein the derivative of melagatran is a prodrug of the formula



wherein R^1 represents linear or branched C_{1-6} alkyl and the OH group replaces one of the amidino hydrogens in Pab.

56. (new) A method as claimed in Claim 55, wherein R¹ represents methyl, ethyl, *n*-propyl, *i*-propyl or *t*-butyl.

57. (new) A method as claimed in Claim 55, wherein R¹ represents ethyl.

58. (new) A method of improving insulin-independency in patients having Type I diabetes mellitus, which method comprises administering a therapeutically-effective amount of melagatran, or a pharmaceutically-acceptable derivative thereof, to a patient in need of such improvement.

59. (new) A method as claimed in Claim 58, wherein the derivative of melagatran is a prodrug of melagatran.

60. (new) A method as claimed in Claim 58, wherein the derivative of melagatran is a prodrug of the formula



wherein R¹ represents linear or branched C₁₋₆ alkyl and the OH group replaces one of the amidino hydrogens in Pab.

61. (new) A method as claimed in Claim 60, wherein R¹ represents methyl, ethyl, *n*-propyl, *i*-propyl or *t*-butyl.

62. (new) A method as claimed in Claim 60, wherein R¹ represents ethyl.

63. (new) A method of treatment of instant blood-mediated inflammatory reaction, which method comprises administering a therapeutically-effective amount of melagatran, or a pharmaceutically-acceptable derivative thereof, to a patient in need of such treatment.

64. (new) A method as claimed in Claim 63, wherein the derivative of melagatran is a prodrug of melagatran.

65. (new) A method as claimed in Claim 63, wherein the derivative of melagatran is a prodrug of the formula



wherein R^1 represents linear or branched C_{1-6} alkyl and the OH group replaces one of the amidino hydrogens in Pab.

66. (new) A method as claimed in Claim 63, wherein R^1 represents methyl, ethyl, *n*-propyl, *i*-propyl or *t*-butyl.

67. (new) A method as claimed in Claim 63, wherein R^1 represents ethyl.

68. (new) A kit of parts comprising components:

(a) a first component comprising melagatran or a pharmaceutically-acceptable derivative thereof; and

(b) a second component comprising cells,

which components (a) and (b) are each provided in a form that is suitable for administration in conjunction with the other.

69. (new) A kit as claimed in Claim 68, wherein the cells are insulin-producing cells or precursors thereof.

70. (new) A kit as claimed in Claim 68, wherein the cells are islets of Langerhans.

71. (new) A kit as claimed in Claim 68, wherein the cells are precursors of insulin-producing cells which are stem cells.

72. (new) A kit as claimed in any one of Claims 68 to 71, wherein the derivative of melagatran is a prodrug of melagatran.

73. (new) A kit as claimed in any one of Claims 68 to 71, wherein the derivative of melagatran is a prodrug of the formula



wherein R¹ represents linear or branched C₁₋₆ alkyl and the OH group replaces one of the amidino hydrogens in Pab.

74. (new) A kit as claimed in Claim 73, wherein R¹ represents methyl, ethyl, *n*-propyl, *i*-propyl or *t*-butyl.

75. (new) A kit as claimed in Claim 73, wherein R¹ represents ethyl.

76. (new) A kit of parts comprising:

- (I) one of components (a) and (b) as defined in any one of Claims 68 to 75 together with
- (II) instructions to use that component in conjunction with the other of the two components.

77. (new) A method of making a kit of parts as defined in any one of Claims 68 to 75, which method comprises bringing a component (a), as defined in any one of Claims 68 to 75, into association with a component (b), as defined in any one of Claims 68 to 75, thus rendering the two components suitable for administration in conjunction with each other.